strong soft guidanc due price
strong indic preliminari revenu growth prior
guidanc soft y/i rev/ep vs rev/ep though
histor initi guidanc conserv actual rev/ep higher
higher lower cost per patient ultomiri vs
soliri higher may like limit upsid maintain neutral view
competit overhang ultomiris/soliri
ep beat higher product sale lower tax expens chart
note provid preliminari y/i revenu growth actual
higher total product sale vs cons/our prior estimate
neg affect fx headwind us/
eu/asia/row account total soliri sale vs
us gmg nmosd patient soliri
estim sale gmg convers ultomiri pnh
remain strong convers rate vs vs
goal convers ahu patient
ultomiri us approv note convers ambit
guidanc revenue/ep growth y/i come short comment
investor day call financi ambit continu deliv double-
digit revenu non-gaap ep growth guidanc high-end total product
sale rel in-lin non-gaap ep guidanc lower vs cons/our
prior estimate chart reflect lower price/pati ultomiri vs soliri convers
continu guidanc assum continu strength neurolog single-digit pnh/
ahu volum growth soliris/ultomiri lower cost pnh mainten dose
ahu dose ultomiri strong strensiq growth off-set strateg price decis
increas invest late-stag program continu license/collabor
guidanc lower ep y/i growth vs revenu growth larg due higher
 higher non-gaap tax rate vs lower soliris/ultomiri
guidanc y/i mid-point vs cons/our prior estimate note
price headwind ultomiri pnh patient enter mainten phase
price discount vs soliri greater price discount ultomiri ahu
lower vs soliri year mitig continu growth neurology/metabol
franchis expand gmg nmosd treat us patient vs
adjust pt vs prior larg higher tax rate
commit expand pipelin beyond franchis revenu
postiv yet see product could meaning way help off-set
futur impact potenti competitor develop thu continu view
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
posit news flow/advanc competitor product would limit materi upsid
today note soliri biosimilar activ enrol
pleas see import disclosur inform page report
estim revenue/ep compound-annual-growth-rate
pt base sum-of-the-part npv
analysi soliris/ultomiri indic includ
pnh ahu gmg
nmo strensiq kanuma
lald wilson diseas
danicopan pnh danicopan
potenti acquisit pharma
pipelin product
price impact biosimilar and/or new
competitor product lower expect
impact vs impact current estim
see fair value-per-share
impact soliris/ultomiri
compet trial competit product
plateau soliris/ultomiri sale compet
biosimilar and/or complement inhibitor
pnh/ahus/gmg enter market
biosimilar and/or new competitor product
success launch activ price
pressur impact market loss see
fair value-per-share
soliris/ultomiri franchis account
total revenu conveni dose
follow-on product ultomiri make effort
fend potenti futur competit pnh ahu gmg
howev think may suffici fulli
protect franchis potenti market entri
biosimilar well new chemic entiti
even soliris/ultomiri maintain major market share
activ price pressur competit affect
revenu growth view
pk-base data ultomiri sc
potenti launch pnh/ahu
data danicopan initi
danicopan pnh start
pnh
data
eu approv ultomiri ahu
data poc studi
initi
time vs hour current
enrol wilson diseas
complet top-lin data
pleas see import disclosur inform page report
upcom event includ initi ultomiri al enrol
wilson diseas complet top-lin data begin
data ultomiri sc potenti launch pnh/ahu
portion initi al amyloidosi vs prior
data danicopan initi danicopan pnh
data data
poc studi initi indic select work on-going initi
waiha start vs prior initi
sc gmg eu approv ultomiri ahu launch high
concentr ultomiri infus time vs hour current start
poc renal basket studi
chart actual vs estim
jefferi visibl alpha factset compani report
pleas see import disclosur inform page report
actualour estimatesconsensusactu vs constot expens rate incom dilut incom dilut share million except per chart guidanc vs consensu estim
factset visibl alpha jefferi compani report
pleas see import disclosur inform page report
